Literature DB >> 33925543

The Impact of Healthcare-Associated Infections in Patients Undergoing Oncological Microvascular Head and Neck Reconstruction: A Prospective Multicentre Study.

Ana Ramos-Zayas1, Francisco López-Medrano2, Irene Urquiza-Fornovi1, Ignacio Zubillaga1, Ramón Gutiérrez1, Gregorio Sánchez-Aniceto1, Julio Acero3, Fernando Almeida3, Ana Galdona3, María José Morán4, Marta Pampin4, José Luis Cebrián4.   

Abstract

(1) Background: Healthcare-associated infections (HAIs) after head and neck free-flap reconstruction are a common postoperative complication. Risk factors for HAIs in this context and their consequences have not been adequately described. (2)
Methods: Ongoing prospective multicentre study between 02/2019 and 12/2020. Demographic characteristics and outcomes were analysed, focusing on infections. (3)
Results: Forty out of 65 patients (61.54%) suffered HAIs (surgical site infection: 52.18%, nosocomial pneumonia: 23.20%, bloodstream infection: 13% and urinary tract infection: 5.80%). Methicillin-resistant Staphylococcus aureus (MRSA) and resistant Pseudomonas aeruginosa, Klebsiella pneumoniae and Enterobacter cloacae were the most frequently implicated. The significant risk factors for infection were: previous radiotherapy (Odds ratio (OR): 5.42; 95% confidence interval (CI), 1.39-21.10), anaemia (OR: 8.00; 95% CI, 0.96-66.95), salvage surgery (eight out of eight patients), tracheostomy (OR: 2.86; 95% CI, 1.01-8.14), surgery duration (OR: 1.01; 95% CI, 1.00-1.02), microvascular reoperation <72 h (eight/eight) and flap loss (eight/eight). The major surgical complications were: a need to reoperate (OR: 6.89; 95% CI, 1.42-33.51), prolonged hospital admission (OR: 1.16; 95% CI, 1.06-1.27) and delay in the initiation of postoperative radiotherapy (OR: 9.07; 95% CI, 1.72-47.67). The sixth month mortality rate in patients with HAIs was 7.69% vs. 0% in patients without HAIs (p = 0.50). (4) Conclusions: HAIs were common after this type of surgery, many of them caused by resistant microorganisms. Some modifiable risk factors were identified. Infections played a role in cancer prognosis by delaying adjuvant therapy.

Entities:  

Keywords:  antibiotic prophylaxis; free flaps; head and neck surgery; healthcare-associated infections; osteoradionecrosis; reconstructive surgery; resistant microorganisms; surgical site infection

Year:  2021        PMID: 33925543     DOI: 10.3390/cancers13092109

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  37 in total

1.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

2.  An analysis of unplanned readmissions after head and neck microvascular reconstructive surgery.

Authors:  A Weyh; R Nocella; M Abdelmalik; R Pucci; A Quimby; A Bunnell; R Fernandes
Journal:  Int J Oral Maxillofac Surg       Date:  2020-05-29       Impact factor: 2.789

Review 3.  Microbiology and principles of antimicrobial therapy for head and neck infections.

Authors:  Itzhak Brook
Journal:  Infect Dis Clin North Am       Date:  2007-06       Impact factor: 5.982

4.  Retrospective health-care associated infection surveillance in oral and maxillofacial reconstructive microsurgery.

Authors:  Márta Patyi; István Sejben; Gábor Cserni; Beáta Sántha; Zoltán Gaál; Júlia Pongrácz; Ferenc Oberna
Journal:  Acta Microbiol Immunol Hung       Date:  2014-12       Impact factor: 2.048

Review 5.  Intraoperative factors associated with free flap failure in the head and neck region: a four-year retrospective study of 216 patients and review of the literature.

Authors:  Y Lin; J-F He; X Zhang; H-M Wang
Journal:  Int J Oral Maxillofac Surg       Date:  2018-09-06       Impact factor: 2.789

6.  Association between operation- and operator-related factors and surgical complications among patients undergoing free-flap reconstruction for head and neck cancers: A propensity score-matched study of 1,865 free-flap reconstructions.

Authors:  Spencer C H Kuo; Pao-Jen Kuo; Yuan-Hao Yen; Peng-Chen Chien; Hsiao-Yun Hsieh; Ching-Hua Hsieh
Journal:  Microsurgery       Date:  2019-06-10       Impact factor: 2.425

7.  Analysis of risk factors for surgical-site infections in 276 oral cancer surgeries with microvascular free-flap reconstructions at a single university hospital.

Authors:  Kazunari Karakida; Takayuki Aoki; Yoshihide Ota; Hiroshi Yamazaki; Mitsunobu Otsuru; Miho Takahashi; Haruo Sakamoto; Muneo Miyasaka
Journal:  J Infect Chemother       Date:  2010-09-01       Impact factor: 2.211

8.  Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer.

Authors:  J R Grandis; C H Snyderman; J T Johnson; V L Yu; F D'Amico
Journal:  Cancer       Date:  1992-10-15       Impact factor: 6.860

9.  How to select candidates for microvascular head and neck reconstruction in the elderly? Predictive factors of postoperative outcomes.

Authors:  Grégoire D'Andréa; Boris Scheller; Jocelyn Gal; Emmanuel Chamorey; Yann Château; Olivier Dassonville; Gilles Poissonnet; Dorian Culié; Pierre-Henri Koulmann; Raphaël Hechema; François Demard; Roxanne Elaldi; Alexandre Bozec
Journal:  Surg Oncol       Date:  2020-04-22       Impact factor: 3.279

10.  Risk factors for complications in clean-contaminated head and neck surgical procedures.

Authors:  D A Girod; T M McCulloch; T T Tsue; E A Weymuller
Journal:  Head Neck       Date:  1995 Jan-Feb       Impact factor: 3.147

View more
  2 in total

Review 1.  Pseudomonas aeruginosa Infections in Cancer Patients.

Authors:  Paulina Paprocka; Bonita Durnaś; Angelika Mańkowska; Grzegorz Król; Tomasz Wollny; Robert Bucki
Journal:  Pathogens       Date:  2022-06-12

2.  Post-Operative Infections in Head and Neck Cancer Surgery: Risk Factors for Different Infection Sites.

Authors:  Giancarlo Pecorari; Giuseppe Riva; Andrea Albera; Ester Cravero; Elisabetta Fassone; Andrea Canale; Roberto Albera
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.